Outcome | Number of event (%) | Linagliptin vs. control | ||
---|---|---|---|---|
Linagliptin (n = 154) | Control (n = 308) | HR (95% CI) | P | |
Primary outcomes | ||||
 6 month follow-up | ||||
  Cardiovascular death | 5 (3.2) | 11 (3.6) | .83 (.29, 2.40) | .735 |
  Non-fatal myocardial infarction | 6 (3.9) | 8 (2.6) | 1.38 (.48, 3.99) | .547 |
  Non-fatal ischemic stroke | 1 (.6) | 3 (1.0) | .62 (.06, 5.95) | .678 |
  Primary composite outcomea | 10 (6.5) | 22 (7.1) | .84 (.40, 1.78) | .648 |
 At the end of follow-up | ||||
  Cardiovascular death | 8 (5.2) | 13 (4.2) | 1.13 (.47, 2.73) | .781 |
  Non-fatal myocardial infarction | 7 (4.5) | 10 (3.2) | 1.29 (.49, 3.38) | .610 |
  Non-fatal ischemic stroke | 3 (1.9) | 3 (1.0) | 1.89 (.38, 9.34) | .438 |
  Primary composite outcomea | 15 (9.7) | 26 (8.4) | 1.08 (.57, 2.03) | .821 |
Secondary outcomes | ||||
 All-cause mortality | 13 (8.4) | 23 (7.5) | 1.07 (.54, 2.12) | .840 |
 Other cardiovascular outcomes | ||||
  Hospitalization for heart failure | 16 (10.4) | 22 (7.1) | 1.41 (.74, 2.69) | .292 |
  Percutaneous coronary intervention | 23 (14.9) | 30 (9.7) | 1.48 (.86, 2.54) | .160 |
  Coronary artery bypass grafting | 4 (2.6) | 6 (1.9) | 1.25 (.35, 4.44) | .727 |
 Safety outcomes | ||||
  Hypoglycemia | 6 (3.9) | 8 (2.6) | 1.43 (.50, 4.12) | .509 |
  DKA or HHS | 1 (.6) | 2 (.6) | .96 (.09, 10.54) | .970 |
  Acute pancreatitis | 0 (.0) | 0 (.0) | NA | NA |
  De novo dialysis | 10 (6.5) | 16 (5.2) | 1.31 (.59, 2.89) | .512 |
  Acute hepatitis | 2 (1.3) | 0 (.0) | NA | NA |
  Newly diagnosed malignancy | 1 (.6) | 5 (1.6) | .38 (.04, 3.25) | .377 |